A 49-Year-Old Woman With Trastuzumab-Deruxtecan-Induced Pneumonitis Responsive to IV Immunoglobulin Therapy After Failed Steroid Treatment

This publication has 8 references indexed in Scilit:

• SEVERE PNEUMONITIS IN PATIENTS RECEIVING THE NOVEL TARGETED CANCER THERAPY, TRASTUZUMAB-DERUXTECAN
  Chest, 2024
• Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
  ESMO Open, 2022
• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
  Journal of Clinical Oncology, 2021
• Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
  Journal for ImmunoTherapy of Cancer, 2021
• New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases
  Current Opinion in Hematology, 2020
• Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
  New England Journal of Medicine, 2020
• Safety of intravenous immunoglobulin (IVIG) therapy
  Autoimmunity Reviews, 2007
• Diagnosis and management of drug-associated interstitial lung disease
  British Journal of Cancer, 2004